FDA Approves LEQEMBI (Lecanemab-Irmb) IV Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
IV Maintenance Dosing for the treatment of Early Alzheimer's Disease Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease ...
Daily12h
Prourokinase Shows No Advantage Over Standard Care for Mild Ischemic Stroke: PUMICE Trial Findings
"The findings of the PUMICE randomized clinical trial indicate that thrombolysis with prourokinase did not demonstrate ...
thecardiologyadvisor.com14h
Statins Lower Risk for Adverse Events in Patients With Newly Diagnosed AF
There is decreased risk for MACE, stroke, and mortality in patients with newly diagnosed atrial fibrillation who regularly use statins.
TMCnet14h
Fresenius Kabi Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora Xi Plasmapheresis System
Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding ...
Rodman & Renshaw sets Talphera stock Buy rating, $4 target
Rodman & Renshaw initiated coverage on shares of biopharmaceutical company Talphera (NASDAQ: TLPH) with a Buy rating and a price target of $4.00. The firm's analysts highlighted Talphera's focus on ...
Le Lézard12h
JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposiumtm 2025
JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") announced today that it will present at the 21st Annual WORLDSymposiumtm 2025, held February 3-7, 2025, in San Diego, Calif. The poster presentations ...
Clinton Herald18h
TO YOUR GOOD HEALTH: Prostate cancer patient gets put under active surveillance
I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One ...